Salutaris Medical Devices

Salutaris Medical Devices (SMD) is a clinical-stage radiotherapeutic company with a focus on pioneering breakthroughs in treating eye diseases with precision radiotherapy. The company has developed the BetaCurve™, a 510k-cleared device aimed at delivering the optimal dose of strontium-90 beta rays to treat challenging disease activity at the back of the eye. SMD's BetaCurve™ has the potential to aid millions of individuals suffering from various conditions, including Advanced Macular Degeneration (wet-AMD), Chronic Central Serous Chorioretinopathy (CCSR), Choroidal Hemangiomas, Early Small Ocular Melanoma, and Choroidal Dysplastic Nevi. Notably, wet-AMD is a leading cause of blindness in seniors globally, and the current treatments involving frequent lifetime eye injections are costly, unpleasant, and inadequate for many patients. The company's current focus is on treating the wet-AMD subtype that poorly responds to existing injection therapy, specifically PCV (polypoidal choroidal vasculopathy). The FDA recently granted clearance for SMD to conduct a pivotal study for PCV, marking a significant milestone. This clearance positions SMD to become the first FDA-approved treatment for the PCV indication, with the radiotherapy aiming to enter the $15 billion injection market (anti-VEGF monotherapy). Established in 2008 and headquartered in the United States, Salutaris Medical Devices presents an innovative approach to addressing unmet needs in eye disease treatment. The $144.48KVenture Round investment at 15 February 2018 bolstered the company's efforts, signaling investor interest in its pioneering radiotherapeutic solutions for challenging eye diseases.